Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2019-03-13 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a specific corporate event: the start of a Phase 1 clinical study for a drug candidate (ABBV-0805) for Parkinson's disease. It includes contact information, a date (March 13, 2019), and a concluding statement about disclosure obligations under the EU Market Abuse Regulation. This format is characteristic of an immediate, high-level announcement of news, rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT). Since it is a press release announcing operational/clinical progress, it does not fit the specific categories like ER (Earnings Release), CAP (Financing), or LTR (Legal). The most appropriate general category for immediate, non-financial regulatory news that doesn't fit elsewhere is Regulatory Filings (RNS), as it is a mandatory disclosure under MAR, or potentially a general announcement. Given the options, RNS serves as the best fit for a general regulatory press release that isn't specifically about earnings, dividends, or management changes.
2019-03-13 English
BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease
Investor Presentation Classification · 1% confidence The document is a press release from BioArctic AB announcing timelines and updates regarding a clinical study (Phase 3) for a drug candidate (BAN2401) in partnership with Eisai. It details study initiation dates, readout targets, and ongoing extension studies. This type of announcement, focusing on clinical trial progress and partnership updates, is typically classified as an Investor Presentation (IP) if it were a detailed deck, or an Earnings Release (ER) if it were summarizing period results. However, since this is a specific, non-periodic update about clinical development timelines and partnership activities, and it is presented as a 'Press release' rather than a formal regulatory filing (like 10-K or IR), it best fits the category for detailed investor-focused materials that aren't strictly earnings or governance reports. Given the options, 'Investor Presentation' (IP) is the closest fit for detailed, forward-looking clinical/pipeline updates aimed at investors, although 'Regulatory Filings' (RNS) is a possibility if it were a mandatory disclosure not covered elsewhere. Since it is a detailed update on a key asset's development timeline, IP is more specific than RNS. It is not an ER as it is not focused on past period financial results, nor is it an RPA as it is the content itself, not an announcement of another report.
2019-03-07 English
BioArctic: Eisai informerar om tidplanen för den enda bekräftande Fas 3-studien med BAN2401 för tidig Alzheimers sjukdom
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces updates regarding the clinical trial timeline for a drug (BAN2401) developed in partnership between BioArctic and Eisai. It details the initiation of a Phase 3 study, expected results timeline, and ongoing open-label extension studies. This type of announcement, focusing on operational updates, clinical progress, and partnership activities, is typically classified as a general regulatory announcement or a specific operational update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal communication to the market about corporate/drug development progress, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for important, non-standard announcements. It is not a specific announcement like a dividend (DIV) or management change (MANG). Given the context of a press release detailing clinical progress, RNS is the most appropriate general classification.
2019-03-07 Swedish
Earnings Release 2018
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké januari – december 2018" (Year-end report January – December 2018) and contains detailed financial tables summarizing performance for the fourth quarter and the full year 2018, including Net Sales, Operating Profit, Net Income, and Earnings Per Share. It also includes a 'Finansiell kalender' listing future reports and the Annual General Meeting (Årsstämma). The content is a comprehensive summary of the full year's financial results and significant business events. Although it contains highlights, the depth of financial data (including detailed tables and notes references) strongly suggests it is the primary annual financial report, which corresponds to the Annual Report (10-K) definition, even if the Swedish term 'Bokslutskommuniké' often precedes the formal 10-K filing. Given the comprehensive nature covering the full fiscal year and the inclusion of detailed financial statements/summaries, 10-K is the most appropriate classification over a simple Earnings Release (ER) or Interim Report (IR). The document length (71,263 chars) also supports it being a full report rather than a short announcement. FY 2018
2019-02-14 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the period January – December 2018, titled 'Full Year Report'. It contains detailed financial statements, including income statements, cash flow data, key ratios, and management commentary (CEO statement, project portfolio updates). It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a 10-K as it is a Swedish company's report (BioArctic AB) and follows the format of an interim/quarterly report covering the full year, which is classified as an Interim/Quarterly Report (IR) in this taxonomy. FY 2018
2019-02-14 English
BioArctics produktkandidat SC0806 för behandling av patienter med komplett ryggmärgsskada är nu i Fas 2
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a specific operational milestone: a product candidate (SC0806) entering Phase 2 of a clinical trial for spinal cord injury. It details the study structure, safety evaluation, and future timelines (interim analysis planned for Q4 2019/Q1 2020). This type of announcement, focusing on clinical trial progression and key operational updates outside of routine financial reporting (like 10-K or ER), is typically classified as a general regulatory announcement or news release. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a formal dividend notice (DIV), it fits best under the general regulatory/news category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard operational news releases that are mandated for public disclosure (as indicated by the EU Market Abuse Regulation disclosure statement at the end). It is not an Earnings Release (ER) as it focuses purely on clinical progress, not financial results.
2019-02-13 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.